Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 4/20 | 1.00 |
| ▸ | GLRA2 | P23416 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PTAFR | P25105 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | GUSB | P08236 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ginkgolide A SCHEMBL340234 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL16452772 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL14029426 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL29493161 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL13808829 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL24818724 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL13702916 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkolide B SCHEMBL29384055 | 0.91 | PTAFR (0.83) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13702686 | 0.87 | GLRA1 (0.77) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13702895 | 0.87 | GLRA1 (0.77) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1768 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005544-A | Method for preparing VA-ECMO lung injury treatment drug by using ginkgolide A to regulate YARS1 | 中国人民解放军总医院第八医学中心 | 2026-05-12 | — | — | CN | claimed |
| CN-122012537-A | Gene GbCYP A6 for promoting synthesis of ginkgolide and application thereof | 扬州大学 | 2026-05-12 | — | — | CN | claimed |
| US-12622941-B2 | Anticoccidial composition comprising ginkgo leaves and use thereof | CJ CHEILJEDANG CORPORATION (KR) | 2026-05-12 | — | — | US | claimed |
| US-12611394-B2 | Use of ginkgolide a in the treatment of autism | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2026-04-28 | — | — | US | claimed |
| EP-4405047-B1 | CANNABINOID FORMULATION FOR ORAL ADMINISTRATION | CB21 PHARMA S R O (CZ) | 2026-04-01 | — | — | EP | claimed |
| US-12569483-B2 | Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-03-10 | — | — | US | claimed |
| EP-3782619-B1 | USE OF GINKGO BILOBA TERPENE LACTONE IN PREPARATION OF DRUGS FOR PREVENTION AND/OR TREATMENT OF TREMORS AND HEALTHCARE PRODUCTS | CHENGDU BAIYU PHARMACEUTICAL CO LTD (CN) | 2026-02-25 | — | — | EP | claimed |
| US-12545694-B2 | Cannabidiol derivatives, preparation method thereof and use thereof | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2026-02-10 | — | — | US | claimed |
| EP-4630413-A1 | FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | Firmenich Incorporated (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250271426-A1 | REDUCTION OF BITTER TASTE OF ACTIVE PHARMACEUTICAL INGREDIENTS AND RELATED ASSAYS AND SCREENING METHODS | FIRMENICH INCORPORATED (US) | 2025-08-28 | — | — | US | claimed |
| US-5512286-A | CONTAINING FLAVONE GLYCOSIDES, GINKGOLIDES AND BILOBALIDES; FREE FROM SERUM-PRECIPITATING AND/OR HAEMAGGLUTINATING COMPONENTS | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1996-04-30 | — | — | US | claimed |
| EP-0431536-B1 | A method of preparation of an extract from Gingko biloba leaves. | SCHWABE WILLMAR GMBH & CO (DE) | 1995-07-19 | — | — | EP | claimed |
| EP-0477968-B1 | Extract from Ginkgo biloba leaves, in particular for intravenous injection or infusion, a method of preparation of the extract and ampoule preparations containing the extract | SCHWABE WILLMAR GMBH & CO (DE) | 1995-05-03 | — | — | EP | claimed |
| EP-0436129-B1 | Active component concentrates and new active component combinations from Ginkgo biloba leaves, their method of preparation and pharmaceuticals containing the active component concentrates or the active component combinations | WALLINGSTOWN COMPANY LIMITED (IE) | 1995-04-12 | — | — | EP | claimed |
| US-5399348-A | Extract from Ginkgo biloba leaves, its method of preparation and pharmaceuticals containing the extract | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1995-03-21 | — | — | US | claimed |
| EP-0431535-B1 | Extract from Ginkgo biloba leaves, its method of preparation and pharmaceuticals containing the extract | SCHWABE WILLMAR GMBH & CO (DE) | 1994-03-02 | — | — | EP | claimed |
| EP-0532512-A4 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS | — | 1993-05-05 | — | — | EP | claimed |
| EP-0532512-A1 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS. | ALLERGAN INC (US) | 1993-03-24 | — | — | EP | claimed |
| WO-1991018608-A1 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS | ALLERGAN, INC. (US) | 1991-12-12 | — | — | WO | claimed |
| US-4734280-A | PLATELET ACTIVATING FACTOR; ANTISHOCK AGENTS, GINKOLIDES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1988-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545694-B2 | Cannabidiol derivatives, preparation method thereof and use thereof | CNR1, CNR2, OPRM1 | GLRA1 132/4885GLRA2 193/4885KMT2A 2899/4885 |
| US-12569483-B2 | Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | PSMB3, THRB, GRIN2B | GLRA1 545/4885GLRA2 293/4885KMT2A 1593/4885 |
| US-12622941-B2 | Anticoccidial composition comprising ginkgo leaves and use thereof | ALPI, SI, SLC10A2 | GLRA1 1920/4885GLRA2 2261/4885KMT2A 3847/4885 |
| US-12611394-B2 | Use of ginkgolide a in the treatment of autism | NR2F2, MECP2, NR2C2 | GLRA1 631/4885GLRA2 96/4885KMT2A 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.